Recommendation of the President – Darzalex (daratumumab)
On 29 December 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 206/2025 on the reimbursement of the medicinal product Darzalex (daratumumab) under the B.54 drug program “Treatment of patients with multiple myeloma (ICD-10: C90.0)”